image: Focusing on the strategy to both adopt AI at speed and scale and harness its potential for economic growth and competitive advantage, the session is moderated by Andrew Nusca, Editorial Director of Fortune Live Media, featuring Barbara Humpton, President and CEO of Siemens, Timothy Wennes, Chief Executive Officer of Santander US, and Rodney Zemmel, Senior Partner and Global Leader of Digital and Firmwide AI at McKinsey & Company.
Credit: Insilico Medicine
From November 11 to 12, the Fortune Global Forum 2024, an invite-only premier event of Fortune, is set to gathers the leaders of the world’s biggest multinational companies on the dynamic frontiers of global business in New York, where business leaders from around the globe come together to create a modern roadmap for success.
Insilico Medicine(“Insilico”), a global leading generative artificial intelligence (AI)-driven biotechnology company, announces that Alex Zhavoronkov PhD, founder and CEO of Insilico Medicine will be attending the Fortune Global Forum 2024, participating in the panel titled “Rewiring Business: Unlocking AI’s Full Economic Potential” at 12:05-1:20 pm ET, November 12.
Focusing on the strategy to both adopt AI at speed and scale and harness its potential for economic growth and competitive advantage, the session is moderated by Andrew Nusca, Editorial Director of Fortune Live Media, featuring Barbara Humpton, President and CEO of Siemens, Timothy Wennes, Chief Executive Officer of Santander US, and Rodney Zemmel, Senior Partner and Global Leader of Digital and Firmwide AI at McKinsey & Company.
Since 1995, the Fortune Global Forum has convened in the world’s top business capitals, providing opportunities to connect with exceptional leaders and shape the future of global business. This November in New York, the brightest minds gather from the world’s largest and most innovative companies, including the Fortune Global 500.
In 2016, Insilico first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal, which laid the foundation for the commercially available Pharma.AI platform. Since then, Insilico keeps integrating technical breakthroughs into Pharma.AI platform, which is currently a generative AI-powered solution spanning across biology, chemistry and clinical development. Powered by Pharma.AI, Insilico has nominated 19 preclinical candidates in its comprehensive portfolio of over 30 assets since 2021 and has received IND approval for 9 molecules.
In early 2024, Insilico published a Nature Biotechnology paper presenting the entire R&D journey from AI algorithms to Phase II clinical trials of ISM001_055, the company’s lead drug pipeline with AI-discovered target and AI-designed structure. Following that, Insilico has recently announced positive preliminary results from a Phase IIa trial (NCT05938920), where ISM001_055 showed dose-dependent response in forced vital capacity (FVC), after only 12 weeks of dosage.
About Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com